Literature DB >> 22440495

Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study.

Masafumi Ueno1, José Luis Ferreiro, Bhaloo Desai, Salvatore D Tomasello, Antonio Tello-Montoliu, Davide Capodanno, Piera Capranzano, Murali Kodali, Kodlipet Dharmashankar, Ronald K Charlton, Theodore A Bass, Dominick J Angiolillo.   

Abstract

OBJECTIVES: This study sought to assess the presence of a dose-response effect of cigarette smoking and its impact on high on-treatment platelet reactivity (HPR) in patients with diabetes mellitus treated with clopidogrel.
BACKGROUND: Cigarette smoking is an inducer of cytochrome P450 1A2, a hepatic enzyme involved in clopidogrel metabolism. If cigarette smoking is associated with a dose-response effect on pharmacodynamic measures in clopidogrel-treated patients is unknown.
METHODS: A total of 134 type 2 diabetes mellitus patients on maintenance aspirin and clopidogrel therapy were studied. Patients were divided into 3 groups according to cotinine levels: <3 ng/ml (nonsmokers), 3 to 199 ng/ml (light smokers), and ≥ 200 ng/ml (heavy smokers). Platelet function was assessed by light transmittance aggregometry, VerifyNow P2Y12 assay (Accumetrics, San Diego, California), and vasodilator-stimulated phosphoprotein. Rates of HPR were defined using established cutoff values.
RESULTS: A dose-response effect was observed for all pharmacodynamic parameters tested. Serum cotinine levels were inversely associated with platelet reactivity as assessed by light transmittance aggregometry using 5 and 20 μmol/l adenosine diphosphate (p < 0.0001 for all). Accordingly, platelet disaggregation increased with levels of serum cotinine (p < 0.0001). Similar results were found with P2Y(12) reaction units (p < 0.0001) and inhibition of platelet aggregation (p = 0.005) as defined by VerifyNow P2Y12 testing, and platelet reactivity index (p = 0.002) as assessed by vasodilator-stimulated phosphoprotein. Higher serum cotinine levels were significantly associated with lower rates of HPR, as defined according to various pharmacodynamic cutoff measures.
CONCLUSIONS: Cigarette smoking is associated with a dose-response effect on clopidogrel-induced antiplatelet effects and lower rates of HPR in diabetes mellitus patients. Copyright Â
© 2012 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22440495     DOI: 10.1016/j.jcin.2011.09.027

Source DB:  PubMed          Journal:  JACC Cardiovasc Interv        ISSN: 1936-8798            Impact factor:   11.195


  15 in total

1.  Effects of cigarette smoking on platelet reactivity during P2Y12 inhibition in patients with myocardial infarction undergoing drug-eluting stent implantation: results from the prospective cigarette smoking on platelet reactivity (COPTER) study.

Authors:  Giuseppe Patti; Marina Polacco; Ester Taurino; Carlo Gaudio; Cesare Greco
Journal:  J Thromb Thrombolysis       Date:  2016-05       Impact factor: 2.300

Review 2.  Cigarette smoking and clopidogrel interaction.

Authors:  Kristopher J Swiger; Omair Yousuf; Kevin P Bliden; Udaya S Tantry; Paul A Gurbel
Journal:  Curr Cardiol Rep       Date:  2013-05       Impact factor: 2.931

3.  Haplotype of platelet receptor P2RY12 gene is associated with residual clopidogrel on-treatment platelet reactivity.

Authors:  Xiao-Yan Nie; Jun-Lei Li; Yong Zhang; Yang Xu; Xue-Li Yang; Yu Fu; Guang-Kai Liang; Yun Lu; Jian Liu; Lu-Wen Shi
Journal:  J Zhejiang Univ Sci B       Date:  2017 Jan.       Impact factor: 3.066

4.  Impact of cigarette smoking on P2Y12 receptor binding activity before and after clopidogrel therapy in patients with coronary artery disease.

Authors:  Jung Rae Cho; Bhaloo Desai; Michael J Haas; Fabiana Rollini; Francesco Franchi; Ana Muñiz-Lozano; Antonio Tello-Montoliu; Elisabetta Ferrante; Luis A Guzman; Theodore A Bass; Dominick J Angiolillo
Journal:  J Cardiovasc Transl Res       Date:  2013-12-20       Impact factor: 4.132

5.  Cigarette smoking and antiplatelet effects of aspirin monotherapy versus clopidogrel monotherapy in patients with atherosclerotic disease: results of a prospective pharmacodynamic study.

Authors:  Fabiana Rollini; Francesco Franchi; Jung Rae Cho; Christopher Degroat; Mona Bhatti; Elisabetta Ferrante; Ronakkumar Patel; Andrew Darlington; Antonio Tello-Montoliu; Bhaloo Desai; Joséluis Ferreiro; Ana Muniz-Lozano; Martin M Zenni; Luis A Guzman; Theodore A Bass; Dominick J Angiolillo
Journal:  J Cardiovasc Transl Res       Date:  2014-01-07       Impact factor: 4.132

Review 6.  Clinical pharmacokinetics and pharmacodynamics of clopidogrel.

Authors:  Xi-Ling Jiang; Snehal Samant; Lawrence J Lesko; Stephan Schmidt
Journal:  Clin Pharmacokinet       Date:  2015-02       Impact factor: 6.447

Review 7.  Platelet function monitoring and clopidogrel.

Authors:  Andrew R Harper; Matthew J Price
Journal:  Curr Cardiol Rep       Date:  2013-01       Impact factor: 2.931

Review 8.  Cardiovascular injury induced by tobacco products: assessment of risk factors and biomarkers of harm. A Tobacco Centers of Regulatory Science compilation.

Authors:  Daniel J Conklin; Suzaynn Schick; Michael J Blaha; Alex Carll; Andrew DeFilippis; Peter Ganz; Michael E Hall; Naomi Hamburg; Tim O'Toole; Lindsay Reynolds; Sanjay Srivastava; Aruni Bhatnagar
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-02-01       Impact factor: 4.733

Review 9.  Platelet function profiles in patients with diabetes mellitus.

Authors:  Fabiana Rollini; Francesco Franchi; Ana Muñiz-Lozano; Dominick J Angiolillo
Journal:  J Cardiovasc Transl Res       Date:  2013-02-13       Impact factor: 4.132

Review 10.  Predictive factors of response to biological disease modifying antirheumatic drugs: towards personalized medicine.

Authors:  Claire I Daïen; Jacques Morel
Journal:  Mediators Inflamm       Date:  2014-01-12       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.